Became pharmacist by fate but in business development and research by choice. Beginning of 2011 two major mergers by two of the top five pharma, each worth more than or around $400 millions, first was Pfizer's deal with Theraclone for infectious diseases and cancer. The other one being Novartis this week which went for cancer diagnostic deal with Genoptix......point to note is Pfizer for long is trying to filln its dry pipeline to sustain the number one position and Novartis knows to survive it has to keep on diversifying its portfolio...as Biomarkers will be the hot spot and major revenue generators for lifestyle diseases in the coming decades.
No comments:
Post a Comment